Longevity Technology

@LongevityTech · London · joined 04 Dec 2018

Daily news and insights on research, investments and technologies that extend life and improve the quality of that extended life. #Longevity

18 694Followers

2 284Following

6 012Posts total

4.1KViews on collected posts

Son gönderiler

Longevity Technology@LongevityTech4 Sep

850 patients signed up for an Alzheimer’s trial needing 760. For @AnnovisBio, that’s the good kind of surprise The pivotal trial has already exceeded its recruitment target, a key milestone for the biotech https://t.co/v8sCTDdyl8 #longevity #alzheimers #biotech #geroscience ht 1.1K views · 6 likes · 2 reposts · 1 replies Open on X →

Longevity Technology@LongevityTech4 Sep

Sergey Young, Founder of BOLD Longevity Growth Fund, on what makes LIC different: bringing science, technology and capital together. 2.5 days in Gstaad with 30+ speakers and investors actively deploying into longevity. Learn more and apply: https://t.co/nG6rbBVg3U #LIC2026 htt 665 views · 6 likes · 1 reposts · 1 replies Open on X →

Longevity Technology@LongevityTech4 Sep

@Veradermics has raised $819.9m as it races to become the first company with an FDA-approved oral drug for hair loss. Late-stage trial data could determine whether its ambition becomes reality https://t.co/aHR8ERiKcl #longevity #hairloss #biotech #drugdevelopment #clinicaltrial 644 views · 0 likes · 0 reposts · 1 replies Open on X →

Longevity Technology@LongevityTech3 Sep

THPharm is using AI to find new uses for a drug already in Phase 3 trials, turning proven biology into a search for new therapeutic opportunities. https://t.co/ayC7jPeXZE #longevity #ai #drugdevelopment #biotech #metabolicdisease @InSilicoMeds https://t.co/uRttkVc8xh 891 views · 9 likes · 5 reposts · 1 replies Open on X →

Longevity Technology@LongevityTech3 Sep

USPTO patent protection strengthens @AlterityT’s ATH434 Parkinson’s investment case through 2045, supporting its long-term development and commercial potential. https://t.co/fpNi01qobG #longevity #parkinsonsdisease #biotech #investment #patents https://t.co/I70rscIcp6 826 views · 4 likes · 1 reposts · 1 replies Open on X →

Aynı büyüklükteki hesaplara karşı

Son 90 güne ait 5 gönderi, 10K–100K takipçi aralığıyla yan yana. boyutuna göre olağan erişim, çoğundan daha zayıf tepki.

Medyan görüntülenme826bu hesap95010K–100K için medyan

Erişim, %4.42%bu hesap3.57%10K–100K için medyan

Etkileşim, %0.86%bu hesap1.96%10K–100K için medyan

Ölçüt	Bu hesap	10K–100K için medyan	Oran
Gönderi başına medyan görüntülenme	826	950	0.87×
Erişim (görüntülenme ÷ takipçi)	4.42%	3.57%	1.24×
Etkileşim oranı	0.86%	1.96%	0.44×

Bu aralıktaki diğer hesaplar → Başka bir hesapla karşılaştır → Bu kıyas değerleri nasıl kuruluyor →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

8263 Sep

891

6444 Sep

665

1.1K

Last 5 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.73%3 Sep

1.68%

0.16%4 Sep

1.50%

0.86%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.96%.

What the audience does

Likes55.6%25 in total

Reposts20.0%9 in total

Replies11.1%5 in total

Quotes4.4%2 in total

Bookmarks8.9%4 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Son gönderiler

Aynı büyüklükteki hesaplara karşı

Growth & engagement

Views per post

Engagement rate per post

What the audience does

Benzer hesaplar